sever
pneumonia
requir
intens
care
unit
icu
admiss
associ
high
rate
morbid
mortal
delay
provis
adequ
antimicrobi
therapi
report
associ
excess
mortal
therefor
rapid
accur
etiolog
diagnosi
sever
pneumonia
essenti
success
treatment
recent
year
bronchoscop
bronchoalveolar
lavag
bal
establish
use
techniqu
collect
lower
respiratori
tract
specimen
alveolar
level
thu
use
accur
defin
caus
organ
pneumonia
howev
convent
cultur
usual
take
least
day
microbiolog
yield
often
compromis
prior
empir
usag
antimicrobi
agent
addit
identif
virus
atyp
organ
requir
separ
etiolog
workup
cellular
analysi
bal
fluid
includ
total
differenti
cell
count
tlymphocyt
ratio
use
diagnosi
variou
interstiti
lung
diseas
appropri
clinic
set
bal
fluid
analysi
provid
highli
suggest
even
diagnost
inform
specif
interstiti
lung
diseas
absenc
lung
biopsi
howev
previou
studi
limit
patient
popul
evalu
role
cellular
analysi
bal
fluid
patient
suspect
pneumonia
studi
focus
differenti
diagnosi
pneumonia
noninfecti
pulmonari
diseas
predict
pneumonia
etiolog
bal
fluid
analysi
perform
within
sever
hour
therefor
analysi
would
use
guid
earli
treatment
could
predict
etiolog
pneumonia
similar
role
cerebrospin
fluid
cellular
analysi
reliabl
differenti
among
mening
etiolog
therefor
studi
investig
whether
analysi
cellular
profil
bal
fluid
predict
etiolog
pneumonia
critic
ill
patient
admit
medic
icu
studi
base
data
prospect
observ
cohort
studi
conduct
march
may
patient
admit
medic
icu
asan
medic
center
tertiari
care
universityaffili
hospit
seoul
republ
korea
suspect
sever
pneumonia
prospect
identifi
monitor
discharg
data
collect
includ
patient
demograph
underli
diseas
condit
ill
sever
score
includ
acut
physiolog
chronic
health
evalu
apach
ii
sequenti
organ
failur
assess
sofa
type
pneumonia
laboratori
data
includ
microbiolog
test
length
icu
stay
outcom
prospect
collect
data
retrospect
analyz
studi
approv
institut
review
board
asan
medic
center
requir
inform
consent
waiv
observ
natur
studi
patient
inform
anonym
deidentifi
prior
analysi
inclus
criteria
follow
patient
age
year
clinic
diagnosi
pneumonia
see
definit
patient
underw
bronchoscop
bal
etiolog
diagnosi
pneumonia
exclus
criteria
follow
patient
pathogen
identifi
patient
bal
fluid
analysi
imposs
due
sever
neutropenia
clot
specimen
perform
patient
mix
infect
identif
bacteria
viru
patient
treat
antimicrobi
agent
hour
bronchoscop
bal
patient
invas
pulmonari
aspergillosi
patient
mycobacteri
infect
patient
pneumocysti
jirovecii
pneumonia
pneumonia
defin
presenc
acut
infiltr
chest
radiograph
least
one
follow
fever
temperatur
hypothermia
temperatur
cough
pleurit
chest
pain
dyspnea
alter
breath
sound
auscult
pneumonia
categor
communityacquir
pneumonia
cap
healthcareassoci
pneumonia
hcap
hospitalacquir
pneumonia
hap
defin
previous
fiberopt
bronchoscopi
bal
perform
follow
standard
protocol
previous
describ
briefli
bal
perform
instil
three
consecut
aliquot
steril
salin
solut
ml
bronchial
tree
area
abnorm
chest
radiographi
right
middl
lobe
lingual
segment
chosen
patient
bilater
diffus
infiltr
bal
fluid
first
retriev
discard
bal
fluid
subsequ
retriev
collect
total
cell
count
determin
use
hemocytomet
correspond
amount
bal
fluid
cell
centrifug
onto
microscop
slide
use
thermo
shandon
cytospin
thermo
fisher
scientif
inc
waltham
usa
rpm
minut
room
temperatur
slide
airdri
stain
wrightgiemsa
stain
differenti
cell
count
includ
percentag
neutrophil
lymphocyt
alveolar
macrophag
eosinophil
determin
bacteri
fungal
mycobacteri
cultur
endotrach
aspir
bal
fluid
perform
respiratori
virus
test
multiplex
reversetranscript
polymeras
chain
reaction
pcr
assay
use
seeplex
ace
detect
kit
seegen
inc
seoul
korea
andor
shell
vial
cultur
pcr
detect
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
urinari
antigen
test
detect
streptococcu
pneumonia
l
pneumophilia
serogroup
speci
also
perform
data
express
mean
standard
deviat
median
interquartil
rang
accord
data
distribut
categor
variabl
compar
use
chisquar
test
fisher
exact
test
appropri
receiv
oper
characterist
roc
curv
construct
determin
perform
bal
fluid
cellular
compon
serum
procalcitonin
concentr
creactiv
protein
concentr
predict
bacteri
pneumonia
youden
index
sensit
use
select
optim
cutoff
point
roc
curv
area
curv
auc
sensit
specif
posit
likelihood
ratio
neg
likelihood
ratio
calcul
posit
neg
predict
valu
preval
bacteri
pneumonia
sever
pneumonia
patient
admit
medic
icu
assum
base
previou
studi
multivari
logist
regress
analysi
use
identifi
independ
predictor
bacteri
pneumonia
variabl
p
valu
less
univari
analysi
includ
multivari
analysi
correl
bal
fluid
white
blood
cell
wbc
count
apach
ii
score
determin
calcul
pearson
correl
coeffici
signific
accept
p
test
perform
use
spss
version
spss
inc
graphpad
prism
version
graphpad
inc
softwar
figur
show
patient
enrol
process
reason
exclus
studi
period
adult
patient
pneumonia
underw
bronchoscop
bal
cap
hcap
hap
patient
exclud
pathogen
identifi
exclud
bal
fluid
analysi
possibl
due
sever
neutropenia
specimen
clot
perform
exclud
two
type
pathogen
identifi
exclud
receiv
antimicrobi
therapi
hour
bronchoscop
bal
ten
patient
pneumocysti
jirovecii
pneumonia
patient
invas
pulmonari
aspergillosi
patient
mycobacteri
pneumonia
also
exclud
final
patient
bacteri
pneumonia
viral
pneumonia
includ
characterist
patient
shown
tabl
thirtytwo
patient
men
mean
age
year
structur
lung
diseas
common
underli
diseas
follow
diabet
mellitu
hematolog
malignancysolid
cancer
sixteen
patient
cap
hcap
hap
baselin
characterist
significantli
differ
bacteri
pneumonia
viral
pneumonia
group
contrast
mean
apach
ii
vs
p
sofa
vs
p
score
significantli
higher
bacteri
pneumonia
group
viral
pneumonia
group
howev
mortal
rate
includ
mortal
significantli
differ
group
pathogen
identifi
patient
summar
tabl
twentyeight
bacteri
pathogen
identifi
patient
patient
two
differ
bacteria
identifi
staphylococcu
aureu
n
common
bacteria
follow
legionella
pneumophila
n
streptococcu
pneumonia
n
bacteria
identifi
bal
fluid
cultur
pcr
patient
endotrach
aspir
sputum
cultur
patient
blood
cultur
patient
urinari
antigen
test
patient
two
patient
pneumococc
antigen
two
patient
legionella
antigen
eleven
patient
two
posit
test
twentysix
virus
identifi
patient
three
patient
two
differ
virus
identifi
rhinoviru
common
viru
n
follow
influenza
viru
n
respiratori
syncyti
viru
n
virus
identifi
bal
fluid
specimen
patient
nasopharyng
specimen
patient
virus
detect
bal
fluid
nasopharyng
sampl
patient
cellular
bal
fluid
profil
distribut
bal
fluid
cell
count
two
group
shown
tabl
figur
detail
data
patient
summar
tabl
median
total
wbc
count
vs
p
percentag
neutrophil
vs
p
absolut
neutrophil
count
vs
p
bal
fluid
significantli
higher
bacteri
pneumonia
group
viral
pneumonia
group
median
serum
procalcitonin
concentr
also
higher
bacteri
pneumonia
group
viral
pneumonia
group
ngml
vs
ngml
p
creactiv
protein
concentr
tend
higher
bacteri
pneumonia
group
viral
pneumonia
group
mgdl
vs
mgdl
p
pathogenidentifi
patient
receiv
antimicrobi
agent
hour
prior
bronchoscop
bal
figur
bacteri
pneumonia
viral
pneumonia
invas
pulmonari
aspergillosi
patient
bacteri
pneumonia
viral
pneumonia
median
durat
antimicrobi
therapi
bronchoscop
bal
day
interquartil
rang
day
median
total
wbc
count
vs
p
percentag
neutrophil
vs
p
significantli
differ
two
group
figur
show
chang
record
bal
fluid
total
wbc
count
percentag
neutrophil
accord
durat
exposur
antimicrobi
agent
abil
bal
fluid
cellular
analysi
distinguish
bacteri
pneumonia
viral
pneumonia
assess
use
roc
analysi
tabl
last
column
figur
total
wbc
count
yield
largest
area
roc
curv
auc
confid
interv
ci
p
follow
neutrophil
count
auc
ci
p
percentag
neutrophil
auc
ci
p
diagnost
valu
bal
fluid
cellular
compon
better
serum
procalcitonin
concentr
auc
ci
creactiv
protein
concentr
auc
ci
sensit
specif
posit
predict
valu
neg
predict
valu
posit
likelihood
ratio
neg
likelihood
ratio
summar
tabl
cutoff
valu
bal
fluid
total
wbc
count
select
use
youden
index
sensit
ci
specif
ci
posit
predict
valu
ci
neg
predict
valu
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
combin
bal
fluid
total
wbc
count
serum
procalcitonin
concentr
ngml
sensit
ci
neg
likelihood
ratio
ci
wherea
bal
fluid
total
wbc
count
serum
creactiv
protein
concentr
mgdl
specif
ci
posit
likelihood
ratio
ci
cutoff
valu
bal
fluid
total
wbc
count
appli
pathogenidentifi
patient
receiv
antimicrobi
agent
hour
sensit
ci
specif
ci
posit
predict
valu
ci
neg
predict
valu
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
multipl
logist
regress
analysi
reveal
bal
fluid
total
wbc
count
independ
predictor
bacteri
pneumonia
adjust
odd
ratio
ci
tabl
modest
signific
posit
correl
degre
bal
leukocytosi
apach
ii
score
r
p
figur
studi
analyz
use
cellular
analysi
bal
fluid
predict
etiolog
pneumonia
critic
ill
adult
patient
neutrophil
pleocytosi
bal
fluid
frequent
found
patient
bacteri
viral
pneumonia
degre
pleocytosi
higher
bacteri
pneumonia
use
differenti
diagnosi
bacteri
pneumonia
total
wbc
count
best
diagnost
accuraci
predict
bacteri
pneumonia
diagnost
perform
better
serum
procalcitonin
creactiv
protein
concentr
combin
bal
fluid
total
wbc
count
serum
procalcitonin
concentr
serum
creactiv
protein
concentr
provid
best
diagnost
yield
data
suggest
cellular
analysi
bal
fluid
rapid
use
techniqu
differenti
bacteri
pneumonia
viral
pneumonia
use
direct
earli
appropri
treatment
inform
role
cellular
profil
bal
fluid
differenti
diagnosi
bacteri
pneumonia
adult
patient
limit
stolz
et
al
evalu
potenti
marker
bacteri
infect
cohort
immunocompromis
patient
pulmonari
complic
report
percentag
neutrophil
bal
fluid
serum
procalcitonin
concentr
independ
predictor
bacteri
infect
suggest
optim
cutoff
valu
percentag
neutrophil
bal
fluid
sensit
specif
much
lower
cutoff
valu
current
studi
sternberg
et
al
investig
use
bal
assess
pneumonia
renal
transplant
patient
suggest
optim
cutoff
valu
percentag
neutrophil
bal
fluid
predict
bacteri
pneumonia
howev
neither
previou
studi
includ
patient
sever
pneumonia
caus
respiratori
virus
alon
compar
bal
find
patient
bacteri
pneumonia
noninfecti
diseas
current
studi
patient
viral
pneumonia
includ
use
newli
develop
multiplex
respiratori
viru
rtpcr
show
case
viral
pneumonia
frequent
associ
neutrophilia
bal
fluid
median
specul
underli
optim
cutoff
valu
percentag
neutrophil
bal
fluid
predict
bacteri
pneumonia
much
higher
current
studi
tabl
previou
studi
sever
author
current
studi
previous
investig
diagnost
util
solubl
trigger
receptor
express
myeloid
bal
fluid
variou
patient
popul
bilater
lung
infiltr
cutoff
valu
neutrophil
bal
fluid
use
differenti
diagnosi
bacteri
fungal
pneumonia
caus
pneumonia
noninfecti
diseas
auc
ci
p
comparison
previou
studi
current
studi
includ
patient
noninfecti
diseas
fungal
pneumonia
includ
much
case
sever
viral
pneumonia
analyz
count
variou
cell
type
among
current
avail
inflammatori
marker
serum
procalcitonin
one
best
indic
bacteri
infect
includ
lower
respiratori
tract
infect
use
serum
procalcitonin
measur
valid
diagnosi
sever
assess
followup
patient
lower
respiratori
tract
infect
current
studi
auc
serum
procalcitonin
concentr
predict
bacteri
pneumonia
auc
smaller
total
wbc
auc
neutrophil
auc
count
combin
bal
fluid
wbc
count
serum
procalcitonin
concentr
tend
improv
diagnost
accuraci
roc
model
indic
combin
marker
use
ruleout
bal
fluid
total
wbc
count
serum
procalcitonin
concentr
ngml
sensit
neg
likelihood
ratio
rulein
bal
fluid
total
wbc
count
serum
creactiv
protein
concentr
mgdl
specif
posit
likelihood
ratio
bacteri
pneumonia
diagnost
accuraci
could
improv
bal
fluid
cellular
profil
interpret
alongsid
clinic
present
radiograph
studi
relev
test
result
use
approach
might
possibl
identifi
patient
manag
without
antibacteri
agent
requir
antivir
agent
although
includ
current
studi
bal
fluid
anoth
notabl
biomark
diagnosi
pneumonia
reportedli
potent
discrimin
bacteri
pneumonia
noninfecti
lung
infiltr
howev
propos
cutoff
valu
concentr
vari
wide
pgml
studi
question
reliabl
bal
fluid
studi
bal
fluid
mainli
confin
patient
ventilatorassoci
pneumonia
therefor
use
etiolog
diagnosi
pneumonia
especi
differenti
diagnosi
viral
pneumonia
elucid
yet
current
studi
directli
compar
patient
bacteri
viral
pneumonia
therefor
differ
previou
studi
bal
fluid
concentr
combin
bal
fluid
cellular
profil
might
exhibit
better
diagnost
perform
although
warrant
studi
strength
current
studi
rel
strict
enrol
criteria
use
minim
bia
associ
antimicrobi
therapi
patient
receiv
antimicrobi
therapi
hour
exclud
regardless
adequaci
prior
antimicrobi
therapi
use
strict
enrol
criteria
howev
small
proport
pneumonia
patient
underw
bronchoscop
bal
final
includ
figur
might
influenc
result
howev
posit
likelihood
neg
likelihood
ratio
influenc
diseas
preval
good
support
valid
data
clinic
practic
result
might
appli
patient
receiv
antimicrobi
therapi
hour
bal
fluid
cellular
analysi
show
evid
pleocytosi
even
antimicrobi
therapi
hour
would
strong
suggest
bacteri
etiolog
studi
sever
limit
first
small
sampl
size
select
critic
ill
patient
popul
analyz
limit
gener
applic
find
moreov
sinc
studi
includ
critic
ill
patient
acut
respiratori
failur
secondari
pneumonia
receiv
antimicrobi
therapi
result
may
applic
major
sever
pneumonia
patient
clinic
practic
second
impact
antimicrobi
therapi
bal
fluid
cellular
profil
inflamm
marker
procalcitonin
remain
elucid
third
case
invas
pulmonari
aspergillosi
pneumocysti
jirovecii
pneumonia
mycobacteri
pneumonia
includ
mainli
patient
type
pneumonia
fourth
patient
noninfecti
caus
pulmonari
infiltr
often
mimic
infecti
caus
acut
respiratori
distress
syndrom
cryptogen
organ
pneumonia
eosinophil
pneumonia
druginduc
pneumon
also
exclud
analys
inclus
case
may
caus
mark
decreas
specif
bal
fluid
criteria
final
pathogen
directli
identifi
bal
fluid
patient
includ
pathogen
identifi
mean
blood
cultur
endotrach
aspir
cultur
urinari
pneumococc
antigen
test
pcr
nasopharyng
sampl
long
clinic
radiograph
compat
etiolog
demonstr
therefor
patient
coincident
upper
respiratori
infect
colon
may
includ
conclus
data
indic
cellular
analysi
bal
fluid
alon
combin
serum
procalcitonin
creactiv
protein
concentr
may
rapidli
provid
valuabl
diagnost
inform
earli
differenti
diagnosi
pneumonia
critic
ill
adult
patient
